BioNotebook: Former Sanofi CEO Viehbacher joins PureTech board; three venture financings, four deals and a dropped drug
This article was originally published in Scrip
Executive Summary
It didn't take long for Chris Viehbacher to jump back in to the world of drug development, although by joining the board of directors of PureTech in Boston he's swimming at the opposite end of the biopharma pool from where he was as CEO of Sanofi back in October.
You may also be interested in...
PureTech Health: Applying Deep Thinking And Business Acumen
Targeting the age-dependent decline in immune function is the aim of a new PureTech Health subsidiary, resTORbio, that has licensed two clinical-stage mTORC1 inhibitors from Novartis.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.